Online inquiry

IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4283MR)

This product GTTS-WQ4283MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4283MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4719MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ15070MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ1214MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ12728MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ7966MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ4402MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ1953MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ1311MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW